



Axovant to Present at 36th Annual J.P. Morgan Healthcare Conference

January 5, 2018

BASEL, Switzerland, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that its Chief Executive Officer David Hung, MD, will be presenting at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th at 10:00 a.m. PST at the Westin St. Francis Hotel in San Francisco. In addition, he will participate in a break-out session immediately following the presentation.

A simultaneous webcast will be available in the "Investors" section of the Company's website at <http://investors.axovant.com>. A replay of the webcast will be available for 30 days following the live event.

About Axovant Sciences

Axovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines to broadly address multiple forms of dementia and related neurological disorders. Axovant is developing a pipeline of product candidates that focuses on the cognitive, functional and behavioral aspects of debilitating conditions such as Alzheimer's disease, Lewy body dementia and other neurological disorders. For more information, visit www.axovant.com.

Contacts:

Investors & Media

Samina Bari

Vice President, Corporate Affairs

investors@axovant.com

media@axovant.com

Media

Brian Reid

W2O Group

breid@w2ogroup.com

402.875.0525

 [Primary Logo](#)

Source: Axovant Sciences Ltd.